Autoinjectors Market Forecast up to 2024
Autoinjectors Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: The medical devices that are primarily used for the self-injection of drugs, classically life-saving drugs, are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.
Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies, advancements in the autoinjectors technology, increasing demand for home healthcare, and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market. Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However, recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.
Market Analysis: The “global autoinjectors market” is estimated to witness a CAGR of 17.1% during the forecast period 2018–2024. The autoinjectors market is analyzed based on three segments – products, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 65% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on the products, the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.
Application Analysis: Based on the application areas, the market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.
Key Players: The major players in the market are Mylan NV, Novartis AG, Amgen, Inc., Becton Dickinson and Company, Bayer AG, and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie, Inc.
Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market. Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool, thus increasing the company’s customer base in recent years.
Benefits: The report provides complete details about the usage and adoption rate of autoinjectors in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Overview: The medical devices that are primarily used for the self-injection of drugs, classically life-saving drugs, are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.
Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies, advancements in the autoinjectors technology, increasing demand for home healthcare, and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market. Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However, recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.
Market Analysis: The “global autoinjectors market” is estimated to witness a CAGR of 17.1% during the forecast period 2018–2024. The autoinjectors market is analyzed based on three segments – products, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 65% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on the products, the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.
Application Analysis: Based on the application areas, the market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.
Key Players: The major players in the market are Mylan NV, Novartis AG, Amgen, Inc., Becton Dickinson and Company, Bayer AG, and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie, Inc.
Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market. Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool, thus increasing the company’s customer base in recent years.
Benefits: The report provides complete details about the usage and adoption rate of autoinjectors in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Total Addressable Market
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Transdermal Drug Delivery
3.4.1.1 Trends of cardiovascular drugs market
3.4.2 Pulmonary Drug Delivery Systems (PDDS)
3.4.3 Insulin Pumps
4 MARKET OUTLOOK
4.1 Cost comparison of EpiPen and its Alternatives
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of Anaphylaxis
5.1.1.2 Rising incidence of chronic disease
5.1.1.3 Increased Development Biologics / Biosimilars
5.1.1.4 Growing demand for home care
5.1.2 Opportunities
5.1.2.1 Increase in healthcare spending
5.1.2.2 Opportunities in emerging market
5.1.2.3 Favorable government policies
5.1.3 Restraints
5.1.3.1 Competition among major vendors
5.1.3.2 Increased product recall
5.1.3.3 High product pricing
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 APPLICATION: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Anaphylaxis
6.3 Multiple Sclerosis
6.4 Rheumatoid Arthritis
6.5 Diabetes
6.6 Others
7 PRODUCT TYPE: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Disposable autoinjector
7.3 Reusable autoinjectors
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.3 Europe
8.3.1 Overview
8.4 Asia Pacific
8.4.1 Overview
8.5 Rest of the World
8.5.1 Overview
9 COMPETITIVE LANDSCAPE
10 VENDORS PROFILE
10.1 Amgen Inc.
10.1.1 Overview
10.1.2 Geographic Presence
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Becton Dickinson and Company
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Mylan N.V.
10.3.1 Overview
10.3.2 Business Segments
10.3.3 Geographic Presence
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 Bayer AG
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Eli Lilly & Company Ltd.
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategies
10.6 Novartis AG
10.6.1 Overview
10.6.2 Business Units
10.6.3 Geographic Presence
10.6.4 Business Focus
10.6.5 SWOT Analysis
10.6.6 Business Strategies
1 VENDORS PROFILE
1.1 Ypsomed Holding AG
1.1.1 Overview
1.2 Biogen Pharmaceuticals
1.2.1 Overview
1.3 Pfizer Inc.
1.3.1 Overview
1.3.2 Highlights
1.4 Teva Pharmaceutical Industries Ltd.
1.4.1 Overview
1.5 Antares Pharma, Inc.
1.5.1 Overview
1.6 Johnson & Johnson
1.6.1 Overview
1.7 AbbVie Inc.
1.7.1 Overview
2 ANNEXURE
Abbreviations
1.1 Industry Overview
1.2 Total Addressable Market
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Transdermal Drug Delivery
3.4.1.1 Trends of cardiovascular drugs market
3.4.2 Pulmonary Drug Delivery Systems (PDDS)
3.4.3 Insulin Pumps
4 MARKET OUTLOOK
4.1 Cost comparison of EpiPen and its Alternatives
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of Anaphylaxis
5.1.1.2 Rising incidence of chronic disease
5.1.1.3 Increased Development Biologics / Biosimilars
5.1.1.4 Growing demand for home care
5.1.2 Opportunities
5.1.2.1 Increase in healthcare spending
5.1.2.2 Opportunities in emerging market
5.1.2.3 Favorable government policies
5.1.3 Restraints
5.1.3.1 Competition among major vendors
5.1.3.2 Increased product recall
5.1.3.3 High product pricing
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 APPLICATION: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Anaphylaxis
6.3 Multiple Sclerosis
6.4 Rheumatoid Arthritis
6.5 Diabetes
6.6 Others
7 PRODUCT TYPE: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Disposable autoinjector
7.3 Reusable autoinjectors
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.3 Europe
8.3.1 Overview
8.4 Asia Pacific
8.4.1 Overview
8.5 Rest of the World
8.5.1 Overview
9 COMPETITIVE LANDSCAPE
10 VENDORS PROFILE
10.1 Amgen Inc.
10.1.1 Overview
10.1.2 Geographic Presence
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Becton Dickinson and Company
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Mylan N.V.
10.3.1 Overview
10.3.2 Business Segments
10.3.3 Geographic Presence
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 Bayer AG
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Eli Lilly & Company Ltd.
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategies
10.6 Novartis AG
10.6.1 Overview
10.6.2 Business Units
10.6.3 Geographic Presence
10.6.4 Business Focus
10.6.5 SWOT Analysis
10.6.6 Business Strategies
1 VENDORS PROFILE
1.1 Ypsomed Holding AG
1.1.1 Overview
1.2 Biogen Pharmaceuticals
1.2.1 Overview
1.3 Pfizer Inc.
1.3.1 Overview
1.3.2 Highlights
1.4 Teva Pharmaceutical Industries Ltd.
1.4.1 Overview
1.5 Antares Pharma, Inc.
1.5.1 Overview
1.6 Johnson & Johnson
1.6.1 Overview
1.7 AbbVie Inc.
1.7.1 Overview
2 ANNEXURE
Abbreviations
LIST OF TABLES
Table 1 AUTOINJECTOR MARKET REVENUE BY APPLICATION SEGMENTATION, 2017–2024 ($MILLION)
Table 2 PREVALENCE OF DIABETES POPULATION FORECASTING BY REGION
Table 3 AUTOINJECTOR MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 4 AMGEN INC.: OFFERINGS
Table 5 AMGEN INC.: RECENT DEVELOPMENTS
Table 6 BECTON DICKINSON AND COMPANY: OFFERINGS
Table 7 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS
Table 1 MYLAN N.V.: OFFERINGS
Table 2 MYLAN N.V.: RECENT DEVELOPMENTS
Table 3 BAYER AG: OFFERINGS
Table 4 BAYER AG: RECENT DEVELOPMENTS
Table 5 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS
Table 6 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS
Table 7 NOVARTIS AG: OFFERINGS
Table 8 NOVARTIS AG: RECENT DEVELOPMENTS
Table 9 YPSOMED HOLDING AG: SNAPSHOT
Table 10 YPSOMED HOLDING AG: RECENT DEVELOPMENTS
Table 11 BIOGEN PHARMACEUTICALS: OVERVIEW
Table 12 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS
Table 13 PFIZER INC. OVERVIEW
Table 14 PFIZER INC.: RECENT DEVELOPMENTS
Table 15 TEVA PHARMACEUTICAL INDUSTRIES LTD. OVERVIEW
Table 16 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
Table 17 ANTARES PHARMA, INC.: OVERVIEW
Table 18 ANTARES PHARMA, INC.: RECENT DEVELOPMENTS
Table 19 JOHNSON & JOHNSON: OVERVIEW
Table 20 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 21 ABBVIE INC.: OVERVIEW
Table 22 ABBVIE INC.: RECENT DEVELOPMENTS
Table 1 AUTOINJECTOR MARKET REVENUE BY APPLICATION SEGMENTATION, 2017–2024 ($MILLION)
Table 2 PREVALENCE OF DIABETES POPULATION FORECASTING BY REGION
Table 3 AUTOINJECTOR MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 4 AMGEN INC.: OFFERINGS
Table 5 AMGEN INC.: RECENT DEVELOPMENTS
Table 6 BECTON DICKINSON AND COMPANY: OFFERINGS
Table 7 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS
Table 1 MYLAN N.V.: OFFERINGS
Table 2 MYLAN N.V.: RECENT DEVELOPMENTS
Table 3 BAYER AG: OFFERINGS
Table 4 BAYER AG: RECENT DEVELOPMENTS
Table 5 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS
Table 6 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS
Table 7 NOVARTIS AG: OFFERINGS
Table 8 NOVARTIS AG: RECENT DEVELOPMENTS
Table 9 YPSOMED HOLDING AG: SNAPSHOT
Table 10 YPSOMED HOLDING AG: RECENT DEVELOPMENTS
Table 11 BIOGEN PHARMACEUTICALS: OVERVIEW
Table 12 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS
Table 13 PFIZER INC. OVERVIEW
Table 14 PFIZER INC.: RECENT DEVELOPMENTS
Table 15 TEVA PHARMACEUTICAL INDUSTRIES LTD. OVERVIEW
Table 16 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
Table 17 ANTARES PHARMA, INC.: OVERVIEW
Table 18 ANTARES PHARMA, INC.: RECENT DEVELOPMENTS
Table 19 JOHNSON & JOHNSON: OVERVIEW
Table 20 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 21 ABBVIE INC.: OVERVIEW
Table 22 ABBVIE INC.: RECENT DEVELOPMENTS
LIST OF CHARTS
Chart 1 RESEARCH METHODOLOGY OF GLOBAL AUTOINJECTOR MARKET
Chart 2 GLOBAL AUTOINJECTORS MARKET REVENUE, 2017-2024 ($MILLION)
Chart 3 SEGMENTATION OF GLOBAL AUTOINJECTOR MARKET
Chart 4 PORTER 5 FORCES OF GLOBAL AUTOINJECTOR MARKET
Chart 5 PEST ANALYSIS OF AUTOINJECTOR MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL AUTOINJECTORS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 AUTOINJECTOR MARKET SEGMENT REVENUE BY APPLICATION, 2017 VS 2024 ($ MILLION)
Chart 10 ANAPHYLAXIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 11 MULTIPLE SCLEROSIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 12 RHEUMATOID ARTHRITIS MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 13 DIABETES AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 14 OTHERS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION, 2017-2024 ($MILLION)
Chart 15 AUTOINJECTOS MARKET SEGMENT SHARE BY TYPE SEGMENTATION, 2017 (%)
Chart 16 DISPOSSABLE AUTOINJECTOR MARKET REVENUE, 2017-2024 ($MILLION)
Chart 17 REUSABLE AUTOINJECTORS MARKET REVENUE, 2017-2024 ($MILLION)
Chart 18 AUTOINJECTOR MARKET BY REGIONAL SEGMENTATION, 2017 (%)
Chart 19 AUTOINJECTORS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
Chart 20 AUTOINJECTOR MARKET REVENUE IN EUROPE, 2017-2024 ($MILLION)
Chart 21 AUTOINJECTORS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 ($MILLION)
Chart 22 AUTO INJECTOR MARKET REVENUE IN REST OF THE WORLD, 2017-2024 ($MILLION)
Chart 23 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 24 AMGEN INC.: GEOGRAPHIC PRESENCE
Chart 25 AMGEN INC.: SWOT ANALYSIS
Chart 26 BECTON DICKINSON AND COMPANY: OVERVIEW SNAPSHOT
Chart 27 BECTON DICKINSON AND COMPANY: BUSINESS UNITS
Chart 28 BECTON DICKINSON AND COMPANY: GEOGRAPHIC REVENUE
Chart 29 BECTON DICKINSON AND COMPANY: SWOT ANALYSIS
Chart 30 MYLAN N.V.: OVERVIEW SNAPSHOT
Chart 31 MYLAN N.V.: BUSINESS SEGMENTS
Chart 32 MYLAN N.V.: GEOGRAPHIC PRESENCE
Chart 33 MYLAN N.V.: SWOT ANALYSIS
Chart 34 BAYER AG: OVERVIEW SNAPSHOT
Chart 35 BAYER AG: BUSINESS UNITS
Chart 36 BAYER AG: GEOGRAPHICAL PRESENCE
Chart 37 BAYER AG: SWOT ANALYSIS
Chart 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT
Chart 39 ELI LILLY & COMPANY LTD.: BUSINESS UNITS
Chart 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE
Chart 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS
Chart 42 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 43 NOVARTIS AG: BUSINESS UNITS
Chart 44 NOVARTIS AG: GEOGRAPHIC PRESENCE
Chart 45 NOVARTIS AG: SWOT ANALYSIS
Chart 1 RESEARCH METHODOLOGY OF GLOBAL AUTOINJECTOR MARKET
Chart 2 GLOBAL AUTOINJECTORS MARKET REVENUE, 2017-2024 ($MILLION)
Chart 3 SEGMENTATION OF GLOBAL AUTOINJECTOR MARKET
Chart 4 PORTER 5 FORCES OF GLOBAL AUTOINJECTOR MARKET
Chart 5 PEST ANALYSIS OF AUTOINJECTOR MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL AUTOINJECTORS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 AUTOINJECTOR MARKET SEGMENT REVENUE BY APPLICATION, 2017 VS 2024 ($ MILLION)
Chart 10 ANAPHYLAXIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 11 MULTIPLE SCLEROSIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 12 RHEUMATOID ARTHRITIS MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 13 DIABETES AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 ($MILLION)
Chart 14 OTHERS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION, 2017-2024 ($MILLION)
Chart 15 AUTOINJECTOS MARKET SEGMENT SHARE BY TYPE SEGMENTATION, 2017 (%)
Chart 16 DISPOSSABLE AUTOINJECTOR MARKET REVENUE, 2017-2024 ($MILLION)
Chart 17 REUSABLE AUTOINJECTORS MARKET REVENUE, 2017-2024 ($MILLION)
Chart 18 AUTOINJECTOR MARKET BY REGIONAL SEGMENTATION, 2017 (%)
Chart 19 AUTOINJECTORS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
Chart 20 AUTOINJECTOR MARKET REVENUE IN EUROPE, 2017-2024 ($MILLION)
Chart 21 AUTOINJECTORS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 ($MILLION)
Chart 22 AUTO INJECTOR MARKET REVENUE IN REST OF THE WORLD, 2017-2024 ($MILLION)
Chart 23 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 24 AMGEN INC.: GEOGRAPHIC PRESENCE
Chart 25 AMGEN INC.: SWOT ANALYSIS
Chart 26 BECTON DICKINSON AND COMPANY: OVERVIEW SNAPSHOT
Chart 27 BECTON DICKINSON AND COMPANY: BUSINESS UNITS
Chart 28 BECTON DICKINSON AND COMPANY: GEOGRAPHIC REVENUE
Chart 29 BECTON DICKINSON AND COMPANY: SWOT ANALYSIS
Chart 30 MYLAN N.V.: OVERVIEW SNAPSHOT
Chart 31 MYLAN N.V.: BUSINESS SEGMENTS
Chart 32 MYLAN N.V.: GEOGRAPHIC PRESENCE
Chart 33 MYLAN N.V.: SWOT ANALYSIS
Chart 34 BAYER AG: OVERVIEW SNAPSHOT
Chart 35 BAYER AG: BUSINESS UNITS
Chart 36 BAYER AG: GEOGRAPHICAL PRESENCE
Chart 37 BAYER AG: SWOT ANALYSIS
Chart 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT
Chart 39 ELI LILLY & COMPANY LTD.: BUSINESS UNITS
Chart 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE
Chart 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS
Chart 42 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 43 NOVARTIS AG: BUSINESS UNITS
Chart 44 NOVARTIS AG: GEOGRAPHIC PRESENCE
Chart 45 NOVARTIS AG: SWOT ANALYSIS
